BTIG raised the firm’s price target on Sionna Therapeutics (SION) to $58 from $50 and keeps a Buy rating on the shares. The firm’s thesis considers the strength of Sionna’s preclinical Cystic Fibrosis Human Bronchial Epithelial assay data, in which Sionna’s Nucleotide Binding Domain 1 candidates were highly active, the analyst tells investors in a research note. The firm likes that Sionna has calibrated its CF HBE to Vertex’s (VRTX) industry gold standard.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SION:
- Sionna Therapeutics price target raised to $58 from $50 at BTIG
- Coty downgraded, Spruce Biosciences initiated: Wall Street’s top analyst calls
- Sionna Therapeutics initiated with an Outperform at LifeSci Capital
- Sionna Therapeutics: NBD1-Targeted CFTR Stabilization Strategy Positions Pipeline for Best-in-Class Efficacy and Blockbuster Upside in Cystic Fibrosis
- Midday Fly By: Nvidia invests in Synopsys, U.S. strikes pharma deal with UK